Literature DB >> 26781979

YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.

Sunisa Thongsom1, Wethaka Chaocharoen1, Atit Silsirivanit2, Sopit Wongkham2, Banchob Sripa3, Han Choe4, Wipa Suginta5,6, Chutima Talabnin7.   

Abstract

YKL-40, a chitinase-like glycoprotein, is expressed at a high level in cancer patients. Its exact function is unknown and is the subject of current investigation. Here, we report the correlation of plasma YKL-40 levels with clinicopathological features of cholangiocarcinoma (CCA), a lethal bile duct cancer, particularly prevalent in Northeastern Thailand. Statistical analysis of plasma YKL-40 concentrations in 57 CCA patients and 41 normal healthy subjects gave a median value of 169.5 ng/mL for CCA patients compared with 46.9 ng/mL for the control subjects (P < 0.0001). There was no significant association of plasma YKL-40 levels with patient age, tumor grade, or histology type. However, Kaplan-Meier analysis suggested that the elevated plasma YKL-40 level was particularly associated with short survival in CCA patients (P = 0.038). Immunohistochemical examination of 34 CCA tissues revealed low expression of YKL-40 in CCA cells, but high expression in adjacent intratumoral stroma, liver, and connective tissues. Univariate analysis showed significant association of the intratumoral YKL-40 expression in CCA tissues with the non-papillary type CCA. Addition of rYKL-40 in the culture medium and transient expression of YKL-40 in CCA cell lines were shown to promote the growth and migration of the tumor cells, and that YKL-40 interacted with a cell-surface receptor involved in the Akt/Erk-mediated pathway. In conclusion, our results support the proposal of YKL-40 as a new candidate prognostic biomarker for cancer diseases.

Entities:  

Keywords:  Chitinase-3-like protein 1; Cholangiocarcinoma; GH-18 glycosyl hydrolases; Prognostic marker; YKL-40

Mesh:

Substances:

Year:  2016        PMID: 26781979     DOI: 10.1007/s13277-016-4838-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  53 in total

1.  CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells.

Authors:  Bo Mi Ku; Yeon Kyung Lee; Jinhyun Ryu; Joo Yeon Jeong; Jungil Choi; Keyoung Mi Eun; Hye Young Shin; Dong Gyu Kim; Eun Mi Hwang; Jae Cheal Yoo; Jae-Yong Park; Gu Seob Roh; Hyun Joon Kim; Gyeong Jae Cho; Wan Sung Choi; Sun Ha Paek; Sang Soo Kang
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

2.  gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells.

Authors:  Kimi C Nishikawa; Albert J T Millis
Journal:  Exp Cell Res       Date:  2003-07-01       Impact factor: 3.905

3.  Serum and tissue level of YKL-40 in endometrial cancer.

Authors:  J T Fan; M J Li; P Shen; H Xu; D H Li; H Q Yan
Journal:  Eur J Gynaecol Oncol       Date:  2014       Impact factor: 0.196

4.  Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma.

Authors:  Ralph A Francescone; Steve Scully; Michael Faibish; Sherry L Taylor; Dennis Oh; Luis Moral; Wei Yan; Brooke Bentley; Rong Shao
Journal:  J Biol Chem       Date:  2011-03-08       Impact factor: 5.157

5.  Structural and thermodynamic insights into chitooligosaccharide binding to human cartilage chitinase 3-like protein 2 (CHI3L2 or YKL-39).

Authors:  Araya Ranok; Jantana Wongsantichon; Robert C Robinson; Wipa Suginta
Journal:  J Biol Chem       Date:  2014-12-04       Impact factor: 5.157

6.  Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma.

Authors:  Kenichi Harada; Shinji Masuda; Makoto Hirano; Yasuni Nakanuma
Journal:  Hum Pathol       Date:  2003-09       Impact factor: 3.466

Review 7.  Cholangiocarcinoma: lessons from Thailand.

Authors:  Banchob Sripa; Chawalit Pairojkul
Journal:  Curr Opin Gastroenterol       Date:  2008-05       Impact factor: 3.287

8.  YKL-40 tissue expression and plasma levels in patients with ovarian cancer.

Authors:  Estrid V S Høgdall; Merete Ringsholt; Claus K Høgdall; Ib Jarle Christensen; Julia S Johansen; Susanne K Kjaer; Jan Blaakaer; Lene Ostenfeld-Møller; Paul A Price; Lise H Christensen
Journal:  BMC Cancer       Date:  2009-01-09       Impact factor: 4.430

9.  Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.

Authors:  Kusumawadee Utispan; Peti Thuwajit; Yoshimitsu Abiko; Komgrid Charngkaew; Anucha Paupairoj; Siri Chau-in; Chanitra Thuwajit
Journal:  Mol Cancer       Date:  2010-01-24       Impact factor: 27.401

10.  High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer.

Authors:  Dong Wang; Bo Zhai; Fengli Hu; Chang Liu; Jinpeng Zhao; Jun Xu
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

View more
  12 in total

1.  Potential suppressive effects of theophylline on human rectal cancer SW480 cells in vitro by inhibiting YKL-40 expression.

Authors:  Hong Peng; Qiang Su; Zhong-Chao Lin; Xiu-Hua Zhu; Ming-Sha Peng; Zhen-Bing Lv
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

Review 2.  Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk.

Authors:  Amal Ahmed Abd El-Fattah; Nermin Abdel Hamid Sadik; Olfat Gamil Shaker; Amal Mohamed Kamal
Journal:  Mediators Inflamm       Date:  2018-10-25       Impact factor: 4.711

3.  HOXA-AS2 promotes type I endometrial carcinoma via miRNA-302c-3p-mediated regulation of ZFX.

Authors:  Ning Song; Ying Zhang; Fanfei Kong; Hui Yang; Xiaoxin Ma
Journal:  Cancer Cell Int       Date:  2020-07-31       Impact factor: 5.722

4.  Influence of YKL-40 gene RNA interference on the biological behaviors of endometrial cancer HEC-1A cells.

Authors:  Lili Li; Jiangtao Fan; Dahai Li; Yan Liu; Poonam Shrestha; Chunyan Zhong; Xiuhong Xia; Xiaobing Huang
Journal:  Oncol Lett       Date:  2018-05-25       Impact factor: 2.967

5.  Functional variant of CHI3L1 gene is associated with neck metastasis in oral cancer.

Authors:  Chun-Wen Su; Mu-Kuan Chen; Wei-Chen Hung; Shun-Fa Yang; Chun-Yi Chuang; Chiao-Wen Lin
Journal:  Clin Oral Investig       Date:  2018-10-19       Impact factor: 3.573

6.  Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness.

Authors:  Simone Brivio; Massimiliano Cadamuro; Mario Strazzabosco; Luca Fabris
Journal:  World J Hepatol       Date:  2017-03-28

7.  Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy.

Authors:  Tengfei Liu; Irina Larionova; Nikolay Litviakov; Vladimir Riabov; Marina Zavyalova; Matvey Tsyganov; Mikhail Buldakov; Bin Song; Kondaiah Moganti; Polina Kazantseva; Elena Slonimskaya; Elisabeth Kremmer; Andrew Flatley; Harald Klüter; Nadezhda Cherdyntseva; Julia Kzhyshkowska
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

8.  Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies.

Authors:  Bingxian Bian; Li Li; Junyao Yang; Yi Liu; Guohua Xie; Yingxia Zheng; Liang Zeng; Junxiang Zeng; Lisong Shen
Journal:  Cancer Cell Int       Date:  2019-10-10       Impact factor: 5.722

9.  Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.

Authors:  Julia S Johansen; Jesper B Andersen; Dan Høgdall; Colm J O'Rourke; Christian Dehlendorff; Ole F Larsen; Lars H Jensen; Astrid Z Johansen; Hien Dang; Valentina M Factor; Mie Grunnet; Morten Mau-Sørensen; Douglas V N P Oliveira; Dorte Linnemann; Mogens K Boisen; Xin W Wang
Journal:  Clin Cancer Res       Date:  2020-09-15       Impact factor: 13.801

10.  Correlation Between Serum Tumor Marker Levels and Connective Tissue Disease-Related Interstitial Lung Disease.

Authors:  Yunqi Bao; Wei Zhang; Dandan Shi; Weili Bai; Dongdong He; Dan Wang
Journal:  Int J Gen Med       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.